RegentAtlantic Capital’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $2.62M | Buy |
3,798
+93
| +3% | +$58.5K | 0.08% | 173 |
|
|
2022
Q2 | $2.19M | Sell |
3,705
-166
| -4% | -$108K | 0.07% | 198 |
|
|
2022
Q1 | $2.7M | Buy |
3,871
+89
| +2% | +$56.3K | 0.08% | 186 |
|
|
2021
Q4 | $2.39M | Buy |
3,782
+13
| +0.3% | +$7.99K | 0.07% | 199 |
|
|
2021
Q3 | $2.28M | Sell |
3,769
-591
| -14% | -$367K | 0.07% | 193 |
|
|
2021
Q2 | $2.44M | Sell |
4,360
-960
| -18% | -$486K | 0.07% | 182 |
|
|
2021
Q1 | $2.52M | Sell |
5,320
-1,189
| -18% | -$579K | 0.09% | 169 |
|
|
2020
Q4 | $3.15M | Sell |
6,509
-6,170
| -49% | -$3.33M | 0.12% | 128 |
|
|
2020
Q3 | $7.1M | Buy |
12,679
+6,121
| +93% | +$3.71M | 0.32% | 66 |
|
|
2020
Q2 | $4.09M | Buy |
6,558
+5,590
| +577% | +$3.17M | 0.23% | 92 |
|
|
2020
Q1 | $473K | Buy |
968
+193
| +25% | +$79.6K | 0.04% | 276 |
|
|
2019
Q4 | $291K | Buy |
+775
| New | +$261K | 0.02% | 386 |
|
|
2019
Q2 | – | Sell |
-532
| Closed | -$218K | – | 444 |
|
|
2019
Q1 | $218K | Sell |
532
-12
| -2% | -$4.94K | 0.02% | 410 |
|
|
2018
Q4 | $203K | Buy |
544
+12
| +2% | +$4.39K | 0.02% | 391 |
|
|
2018
Q3 | $215K | Sell |
532
-100
| -16% | -$38.1K | 0.02% | 414 |
|
|
2018
Q2 | $218K | Hold |
632
| – | – | 0.02% | 383 |
|
|
2018
Q1 | $218K | Buy |
632
+60
| +10% | +$20.9K | 0.02% | 391 |
|
|
2017
Q4 | $215K | Buy |
572
+35
| +7% | +$14.2K | 0.02% | 404 |
|
|
2017
Q3 | $240K | Hold |
537
| – | – | 0.02% | 377 |
|
|
2017
Q2 | $264K | Buy |
537
+5
| +0.9% | +$2.19K | 0.02% | 351 |
|
|
2017
Q1 | $206K | Sell |
532
-30
| -5% | -$11.1K | 0.02% | 382 |
|
|
2016
Q4 | $206K | Buy |
562
+10
| +2% | +$3.8K | 0.02% | 375 |
|
|
2016
Q3 | $222K | Buy |
+552
| New | +$221K | 0.02% | 359 |
|
|
2016
Q1 | – | Sell |
-532
| Closed | -$289K | – | 390 |
|
|
2015
Q4 | $289K | Sell |
532
-1
| -0.2% | -$542 | 0.03% | 316 |
|
|
2015
Q3 | $248K | Hold |
533
| – | – | 0.02% | 332 |
|
|
2015
Q2 | $272K | Hold |
533
| – | – | 0.02% | 324 |
|
|
2015
Q1 | $241K | Sell |
533
-56
| -10% | -$23.7K | 0.02% | 323 |
|
|
2014
Q4 | $242K | Hold |
589
| – | – | 0.02% | 329 |
|
|
2014
Q3 | $212K | Buy |
+589
| New | +$197K | 0.02% | 343 |
|
|
2014
Q2 | – | Sell |
-851
| Closed | -$256K | – | 364 |
|
|
2014
Q1 | $256K | Buy |
+851
| New | +$262K | 0.03% | 311 |
|
|
2013
Q4 | – | Sell |
-1,560
| Closed | -$488K | – | 359 |
|
|
2013
Q3 | $488K | Buy |
+1,560
| New | +$410K | 0.05% | 234 |
|
Other funds holding REGN
RegentAtlantic Capital's REGN Position: Q3 2022 in Review
RegentAtlantic Capital increased its Regeneron Pharmaceuticals (REGN) stake by 2.5% in Q3 2022, buying an estimated $58.5K and bringing the position to 3,798 shares worth $2.62M. The position accounts for 0.08% of the portfolio, ranked #173.
RegentAtlantic Capital first reported a position in REGN in Q3 2013 and has held it in 31 quarters since. The position peaked at $7.1M in Q3 2020. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.
- RegentAtlantic Capital held 3,798 shares of Regeneron Pharmaceuticals worth $2.62M as of Q3 2022.
- RegentAtlantic Capital bought 93 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $58.5K.
- Regeneron Pharmaceuticals made up 0.08% of RegentAtlantic Capital's portfolio in Q3 2022, its #173 holding.
- RegentAtlantic Capital first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 31 quarters since.
- RegentAtlantic Capital's Regeneron Pharmaceuticals position peaked at $7.1M in Q3 2020.
- 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.